



GLOBAL VACCINE ACTION PLAN

MONITORING, EVALUATION & ACCOUNTABILITY
SECRETARIAT ANNUAL REPORT 2020

Global vaccine action plan: monitoring, evaluation and accountability. Secretariat annual report 2020
ISBN 978-92-4-001432-9 (electronic version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Global vaccine action plan: monitoring, evaluation and accountability. Secretariat annual report 2020. Geneva: World Health Organization; 2020. Licence: [CC BY-NC-SA 3.0 IGO](#).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

GLOBAL VACCINE ACTION PLAN

MONITORING, EVALUATION & ACCOUNTABILITY
SECRETARIAT ANNUAL REPORT 2020

Note:

In line with the reporting in 2019, this year's annual GVAP secretariat report presents a collection of figures and graphs with the latest available data, for a selection of GVAP indicators, mainly covering disease elimination, coverage and equity and the surveillance dimensions. For some indicators, succinct notes complement the figures. For indicators which have not been updated this year, as well as for all background references and sources, please refer to the [2018 GVAP secretariat report](#).

For indicators related to supply and financing, a [Global vaccine market report](#) will be published in September 2020 on the WHO webpage (www.who.int/immunization/MI4A).

Vaccine coverage data displayed in this report are based on the July 2020 revised time series of the WHO-UNICEF estimates of national immunization coverage 2010–2019.

The majority of data provided in this report were updated through the end of December 2019. This means that there is no direct impact of the COVID-19 pandemic depicted in this report, which only started to impact countries in the first quarter of 2020. Nevertheless there is an indirect impact that is measurable: reporting of immunization figures was less exhaustive than in previous years due to the workload on COVID-19 response in 2020.



CONTENTS

ABBREVIATIONS.....	IV
BOX 1: PROGRESS TOWARDS MEETING CORE GVAP INDICATORS – 2020 REPORT.....	V
1. DISEASE ELIMINATION	1
2. IMMUNIZATION COVERAGE AND EQUITY.....	6
3. EXCEED THE MILLENNIUM DEVELOPMENT GOAL 4 TARGET FOR REDUCING CHILD MORTALITY AND INTEGRATION INDICATORS	15
4. ENSURING COUNTRY OWNERSHIP OF IMMUNIZATION	18
5. STRONG IMMUNIZATION SYSTEMS ARE AN INTEGRAL PART OF A WELL-FUNCTIONING HEALTH SYSTEM	21
6. VACCINE SAFETY	24

ABBREVIATIONS

AEFI	adverse events following immunization
cVDPV	circulating vaccine-derived poliovirus cases
DTP	diphtheria–tetanus–pertussis-containing vaccines
DTP1	diphtheria–tetanus–pertussis-containing vaccines, first dose
DTP3	diphtheria–tetanus–pertussis-containing vaccines, third dose
HepB BD	Hepatitis B vaccine, birth dose
IB-VPD	invasive bacterial vaccine-preventable diseases
IPV	inactivated poliovirus vaccines
MCV	measles-containing vaccines
MCV2	measles-containing vaccine, second dose
MDG	Millennium Development Goal
MNT	maternal and neonatal tetanus
PCV	pneumococcal conjugate vaccine
PCV3	pneumococcal conjugate vaccine, third dose
RCV	rubella-containing vaccines
RCV1	rubella-containing vaccines, first dose
UNICEF	United Nations Children's Fund
WEUNIC	WHO/UNICEF Estimates of National Immunization Coverage
WHO	World Health Organization
WPV1	wild poliovirus serotype 1

Box 1: Progress towards meeting core GVAP indicators – 2020 report

Goal /Strategic objective	Indicators	
GOALS		
Achieve a world free of poliomyelitis	G1.1 Interrupt wild poliovirus transmission globally	Fig. 1, Fig. 2, Fig. 3
	G1.2 Certification of poliomyelitis eradication	
Meet global and regional elimination targets	G2.1 Maternal and neonatal tetanus elimination	Fig. 4, Fig. 5
	G2.2 Measles elimination	Fig. 6, Table 1
	G2.3 Rubella/congenital rubella syndrome (CRS) elimination	Fig. 7, Table 2
Meet vaccination coverage targets in every region, country and community	G3.1 By 2015, reach 90% national coverage and 80% in every district or equivalent administrative unit with three doses of diphtheria–tetanus–pertussis-containing vaccines	Fig. 8, Fig. 9, Fig. 10, Fig. 11, Fig. 12, Fig. 13, Fig. 14
	G3.2 By 2020, reach 90% national coverage and 80% in every district or equivalent administrative unit for all vaccines in national programmes, unless otherwise recommended	Fig. 15, Fig. 16, Fig. 17
Develop and introduce new and improved vaccines and technologies	G4.3 Number of low-income and middle-income countries that have introduced one or more new or under-utilized vaccines	Fig. 18
Exceed the MDG Goal 4 target for reducing child mortality and Integration indicators	G5.1 Reduce under-five mortality rate	Fig. 19, Fig. 20
STRATEGIC OBJECTIVES (SOs)		
Ensuring country ownership of immunization	SO1.2 Presence of an independent technical advisory group that meets the defined criteria	Fig. 21, Fig. 22
The benefits of immunization are equitably extended to all people	SO3.1 Percentage of districts with 80% or greater coverage with three doses of diphtheria–tetanus–pertussis-containing vaccine	Fig. 13
	SO3.2 Reduction in coverage gaps between wealth quintiles and other appropriate equity indicator(s)	Fig. 14
Strong immunization systems are an integral part of a well-functioning health system	SO4.1 Drop-out rates between first dose (DTP1) and third dose (DTP3) of diphtheria–tetanus–pertussis-containing vaccines	Fig. 9
	SO4.2 Sustained coverage of diphtheria–tetanus–pertussis-containing vaccines 90% or greater for three or more years	Fig. 12
	SO4.4 Number of countries meeting established surveillance standards with case-based surveillance for vaccine-preventable diseases and with viral and bacterial laboratory confirmation of suspect or probable cases	Fig. 23, Fig. 24, Table 3
Vaccine safety		Fig. 25



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24540

